Stiris Research Inc. awarded extension of Phase II Hormone Refractory Castrate-Resistant Prostate Cancer (HRCPC) study

London, ON — July 17, 2017 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces it will be partnering with a specialty pharmaceutical company to ensure safety of subjects with HRCPC previously treated with its oral anti-androgen in a Phase II trial.

“We are pleased to be the partner of choice.  Our expertise in this therapeutic area and specifically with development of this molecule will ensure we can effectively and efficiently support this trial,” said Kara Lee McWatters, Clinical Project Director.

Prostate cancer is the most common cancer among men (after skin cancer).  About one man in nine will be diagnosed with prostate cancer during his lifetime.  Prostate cancer is the second leading cause of cancer death in American men, behind lung cancer.  About 1 in 41 men will die from prostate cancer.  Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it.  More than 2.9 million men in the United States diagnosed with prostate cancer are still alive today.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.